OTCMKTS:TRLPF - Acerus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.1540 0.00 (0.00 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$0.1540
Today's Range$0.1540 - $0.1540
52-Week Range$0.0750 - $0.4036
VolumeN/A
Average Volume2,238 shs
Market Capitalization$37.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.66
Acerus Pharmaceuticals logoAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive TRLPF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TRLPF
CUSIPN/A
Phone416-679-0771

Debt

Debt-to-Equity Ratio0.60
Current Ratio1.52
Quick Ratio0.97

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.44 million
Price / Sales5.63
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book5.13

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-8,710,000.00
Net Margins-198.08%
Return on Equity-206.42%
Return on Assets-69.23%

Miscellaneous

Employees17
Outstanding Shares235,240,000
Market Cap$37.43 million

Acerus Pharmaceuticals (OTCMKTS:TRLPF) Frequently Asked Questions

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) released its earnings results on Wednesday, March, 18th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. Acerus Pharmaceuticals had a negative return on equity of 206.42% and a negative net margin of 198.08%. View Acerus Pharmaceuticals' Earnings History.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Acerus Pharmaceuticals.

Who are some of Acerus Pharmaceuticals' key competitors?

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the folowing people:
  • Mr. Ken Yoon, Chief Financial Officer
  • Ms. Patricia Symmes, Chief Operating Officer
  • Dr. Nathan Bryson, Chief Scientific Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Edward Gudaitis, Pres , CEO & Director

Has Acerus Pharmaceuticals been receiving favorable news coverage?

News coverage about TRLPF stock has trended somewhat positive on Saturday, according to Accern. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Acerus Pharmaceuticals earned a media and rumor sentiment score of 0.02 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 45.53 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Acerus Pharmaceuticals.

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acerus Pharmaceuticals' stock price today?

One share of TRLPF stock can currently be purchased for approximately $0.1540.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of $37.43 million and generates $6.44 million in revenue each year. Acerus Pharmaceuticals employs 17 workers across the globe.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]


MarketBeat Community Rating for Acerus Pharmaceuticals (OTCMKTS TRLPF)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe TRLPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRLPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.